Loading
companiesCompany
TG Therapeutics
TG Therapeutics is a New York company whose lymphoma drug umbralisib was approved in 2021 and withdrawn in 2022 over a survival signal, and which now sells the anti-CD20 antibody ublituximab for multiple sclerosis.
Also called: TG Therapeutics, Inc.
Overview
TG Therapeutics, listed on Nasdaq, developed the PI3K-delta and CK1-epsilon inhibitor umbralisib (Ukoniq), which received accelerated approval in 2021 for relapsed marginal zone and follicular lymphoma and was withdrawn in 2022 after the UNITY-CLL trial suggested a possible detriment in overall survival, and the glycoengineered anti-CD20 antibody ublituximab, which it had studied with umbralisib in chronic lymphocytic leukaemia and which is now approved as Briumvi for relapsing multiple sclerosis. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Headquarters
New York, NY, US
Scorecard
All companies#332of 1244 companies, score 12
- targets +2
- modalities +2
- regions +1
- registry trials +10
- failures -3
0 approved, 0 in phase 3, 0 earlier, 1 targets, 24 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
WithdrawnOral PI3Kδ / CK1ε inhibitor
Umbralisib · Ukoniq
A PI3K inhibitor for marginal zone and follicular lymphoma approved in 2021 and withdrawn in 2022 after the UNITY-CLL trial suggested more deaths.
Similar pages
- TrialStudy to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
Shares Umbralisib, Chronic lymphocytic leukaemia.
- TrialAcalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
Shares Umbralisib, Chronic lymphocytic leukaemia.
- CompanySecuraBio
Shares PI3K delta (PIK3CD), Follicular lymphoma, Chronic lymphocytic leukaemia.
- CompanyMEI Pharma
Shares PI3K delta (PIK3CD), Follicular lymphoma.
- TrialStudy to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Shares Umbralisib, Follicular lymphoma.
- TreatmentCopanlisib
Shares PI3K delta (PIK3CD), Follicular lymphoma.
- TreatmentIdelalisib
Shares PI3K delta (PIK3CD), Follicular lymphoma, Chronic lymphocytic leukaemia.
- PersonBarbara Eichhorst
Shares CD20, Chronic lymphocytic leukaemia.